BackgroundErtugliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, is approved for the glycemic management of patients with type 2 diabetes.
Bingjie Xue +6 more
doaj +1 more source
Knowledge mapping of alström syndrome research: a bibliometric and visualization analysis based on WoS data from 2000 to 2025. [PDF]
Zhang H +10 more
europepmc +1 more source
Phosphoproteomic profiling highlights CDC42 and CDK2 as key players in the regulation of the TGF-β pathway in ALMS1 and BBS1 knockout models. [PDF]
Bea-Mascato B +6 more
europepmc +1 more source
Type 1 Diabetes Mellitus in a Child With Genetically Confirmed Alström Syndrome: An Unusual Autoimmune Phenotype. [PDF]
Alquraishi AS +3 more
europepmc +1 more source
Comparison and Characteristics of MASLD Mouse Models. [PDF]
Wei L, Gao C, Qin H.
europepmc +1 more source
Adult-Onset Diabetes and Liver Fibrosis as Diagnostic Clues to Alström Syndrome: A Case Report. [PDF]
Balogun F +5 more
europepmc +1 more source
Elucidating the genetic landscape of inherited retinal disorders in India. [PDF]
Mathias GP +6 more
europepmc +1 more source
The Mechanism and Regulation of Disulfidptosis and Its Role in Disease. [PDF]
Wan Y +7 more
europepmc +1 more source
Integrating Multiomics and Machine Learning: Senescence-Regulated ALMS1-IT1/miR-7c-5p/HMGA2 Axis as a Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma. [PDF]
Zhu Y +12 more
europepmc +1 more source

